Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""McMurray JJ"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 61-80 z 192
Tytuł:
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
Autorzy:
Senni M; Cardiology, Heart Failure and Heart Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Piazza OMS, 24127, Bergamo, Italy.
McMurray JJ; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Wachter R; University Medicine Goettingen, Clinic for Cardiology and Pneumology, Goettingen, Germany.
McIntyre HF; Hon Reader in Medicine, Brighton and Sussex Medical School, UK.
Reyes A; University Hospital Virgen de Valme, Medicina Interna, Sevilla, Spain.
Majercak I; Outpatient Internal Medicine, Cardiology, Kosice, Slovakia.
Andreka P; Gottsegen Gyorgy, Orszagos Kardiologiai Intezet, Felnott Kardiologiai Osztaly, Budapest, Hungary.
Shehova-Yankova N; MHAT Bratan Shukerov, Cardiology Department, Smolian, Bulgaria.
Anand I; Veterans Medical Center -Minneapolis, Minneapolis, MN, USA.
Yilmaz MB; Cumhuriyet University Medical Faculty Cardiology, Sivas, Turkey.
Gogia H; Cardiology Consultants of Orange County, Anaheim, CA, USA.
Martinez-Selles M; Hospital Gregorio Maranon, Servicio de Cardiologia, and Universidad Europea y Universidad Complutense, Madrid, Spain.
Fischer S; Praxis Dr Fischer, Leipzig, Germany.
Zilahi Z; Kardiologiai Szakrendeles, Nyiregyháza, Hungary.
Cosmi F; P.O. Ospedale Valdichiana S. Margherita, U.O. di Cardiologia, Cortona, Italy.
Gelev V; MHAT Tokuda Hospital Sofia, Clinic of Cardiology and Angio, Sofia, Bulgaria.
Galve E; Hospital Vall D'Hebron, Cardiology, Paseo Valle de Hebron, Barcelona, Spain.
Gómez-Doblas JJ; Hospital Virgen de la Victoria, Cardiologia, Campus Universitario Teatinos, Malaga, Spain.
Nociar J; Kardio 1 s.r.o., Lucenec, Slovakia.
Radomska M; Letesia s.r.o., Trebisov, Slovakia.
Sokolova B; Galenum s.r.o., Ambulancia v odbore Vutorne Lekarstvo, Bratislava, Slovakia.
Volterrani M; IRCCS San Raffaele Pisana, Rome, Italy.
Sarkar A; Novartis HC Ltd, Hyderabad, India.
Reimund B; Novartis Pharma AG, Basel, Switzerland.
Chen F; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Charney A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Sep; Vol. 18 (9), pp. 1193-202. Date of Electronic Publication: 2016 May 12.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Aminobutyrates/*administration & dosage
Angiotensin Receptor Antagonists/*administration & dosage
Heart Failure/*drug therapy
Neprilysin/*antagonists & inhibitors
Tetrazoles/*administration & dosage
Aged ; Biphenyl Compounds ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Hyperkalemia/chemically induced ; Hypotension/chemically induced ; Male ; Middle Aged ; Renal Insufficiency/chemically induced ; Treatment Outcome ; Valsartan
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Autorzy:
Chin KL; Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia.
Collier TJ; London School of Hygiene and Tropical Medicine, London, UK.
Pitt B; University of Michigan School of Medicine, Ann Arbor, MI, USA.
McMurray JJ; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.; National Heart and Lung Institute, Imperial College, London, UK.
van Veldhuisen DJ; University of Groningen, Groningen, The Netherlands.
Pocock SJ; London School of Hygiene and Tropical Medicine, London, UK.
Vincent J; Pfizer, New York, USA.
Turgonyi E; Pfizer, New York, USA.
Zannad F; CHU and University Henri Poincaré, Nancy, France.
Krum H; Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia.
Pokaż więcej
Corporate Authors:
EMPHASIS-HF Study Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Sep; Vol. 18 (9), pp. 1175-81. Date of Electronic Publication: 2016 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Aspirin/*therapeutic use
Heart Failure, Systolic/*drug therapy
Mineralocorticoid Receptor Antagonists/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Spironolactone/*analogs & derivatives
Aged ; Blood Pressure ; Chronic Disease ; Drug Interactions ; Eplerenone ; Female ; Glomerular Filtration Rate ; Heart Failure, Systolic/physiopathology ; Humans ; Male ; Potassium/blood ; Proportional Hazards Models ; Spironolactone/therapeutic use ; Stroke Volume
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
Autorzy:
Cannon JA; Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, Scotland, UK.
Shen L; Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, Scotland, UK.
Jhund PS; Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, Scotland, UK.
Anand IS; Division of Cardiology, University of Minnesota, Minneapolis, MN, USA.
Komajda M; Université Paris 6 and Hospital Pitié-Salpétrière, Paris, France.
McKelvie RS; Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
Zile MR; Ralph H. Johnsons Veterans Affairs Medical Center and, Medical University of South Carolina, Charleston, SC, USA.
Carson PE; Georgetown University and Washington DC Veterans Affairs Medical Center, Washington, DC, USA.
McMurray JJ; Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, Scotland, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Aug; Vol. 18 (8), pp. 1021-31. Date of Electronic Publication: 2016 May 15.
Typ publikacji:
Journal Article
MeSH Terms:
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Biphenyl Compounds/*therapeutic use
Bundle-Branch Block/*physiopathology
Heart Failure/*drug therapy
Tetrazoles/*therapeutic use
Aged ; Bundle-Branch Block/complications ; Cause of Death ; Female ; Heart Failure/blood ; Heart Failure/complications ; Heart Failure/physiopathology ; Hospitalization/statistics & numerical data ; Humans ; Irbesartan ; Male ; Middle Aged ; Mortality ; Natriuretic Peptide, Brain/blood ; Peptide Fragments/blood ; Prognosis ; Proportional Hazards Models ; Severity of Illness Index ; Stroke Volume ; Systole
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges.
Autorzy:
Hawkins NM; Division of Cardiology, University of British Columbia, Vancouver, Canada.
Virani SA; Division of Cardiology, University of British Columbia, Vancouver, Canada.
Sperrin M; Centre for Health Informatics, Institute of Population Health, University of Manchester, Manchester, UK.
Buchan IE; Centre for Health Informatics, Institute of Population Health, University of Manchester, Manchester, UK.
McMurray JJ; Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Krahn AD; Division of Cardiology, University of British Columbia, Vancouver, Canada.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Aug; Vol. 18 (8), pp. 977-86. Date of Electronic Publication: 2015 Dec 14.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Cardiac Resynchronization Therapy Devices*
Defibrillators, Implantable*
Monitoring, Ambulatory*
Heart Failure/*diagnosis
Cardiography, Impedance ; Disease Progression ; Heart Failure/physiopathology ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489].
Autorzy:
Anker SD; Innovative Clinical Trials, Department of Cardiology & Pneumology, University Medical Center Göttingen (UMG), Germany.
Schroeder S; Bayer Pharma AG, Berlin, Germany.
Atar D; Department of Cardiology B, Oslo University Hospital Ulleval and University of Oslo, Norway.
Bax JJ; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Ceconi C; Unit of Cardiology, Hospital of Desenzano del Garda, Desenzano del Garda, Italy.
Cowie MR; National Heart and Lung Institute, Imperial College London, London, UK.
Crisp A; GlaxoSmithKline, Middlesex, UK.
Dominjon F; Servier International, Paris, France.
Ford I; Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Ghofrani HA; University of Giessen and Marburg Lung Center, UGMLC [member of the German Center for Lung Research (DZL)], Giessen, Germany.; Kerckhoff-Klinik Bad Nauheim, Germany.; Imperial College London, UK.
Gropper S; Boehringer-Ingelheim GmBH & Co. KG, Ingelheim, Germany.
Hindricks G; Department of Electrophysiology, Heart Center, University of Leipzig, Leipzig, Germany.
Hlatky MA; Stanford University School of Medicine, Stanford, CA, USA.
Holcomb R; Independent Biostatistician, Minneapolis, MN, USA.
Honarpour N; Amgen, Inc., Thousand Oaks, CA, USA.
Jukema JW; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Kim AM; Pfizer, Inc., Cambridge, MA, USA.
Kunz M; Bayer Pharma AG, Berlin, Germany.
Lefkowitz M; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Floch CL; Servier International, Paris, France.
Landmesser U; Department of Cardiology, Charité Universitätsmedizin Berlin, Berlin, Germany.
McDonagh TA; King's College Hospital, London, UK.
McMurray JJ; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Merkely B; Semmelweis University Heart and Vascular Center, Budapest, Hungary.
Packer M; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Prasad K; United Kingdom Medicines and Healthcare Products Regulatory Agency, London, UK.
Revkin J; Pfizer, Inc., Cambridge, MA, USA.
Rosano GM; IRCCS San Raffaele Hospital Roma, Rome, Italy.; Cardiovascular and Cell Sciences Institute, St. George's University of London, London, UK.
Somaratne R; Amgen, Inc., Thousand Oaks, CA, USA.
Stough WG; Campbell University College of Pharmacy and Health Sciences, NC, USA.
Voors AA; University of Groningen, Groningen, The Netherlands.
Ruschitzka F; Department of Cardiology, Heart Failure Clinic and Transplantation, University Heart Center Zurich, Zurich, Switzerland.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Jun; Vol. 18 (6), pp. 727.
Typ publikacji:
Journal Article; Published Erratum
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.
Autorzy:
Anker SD; Innovative Clinical Trials, Depar tment of Cardiology & Pneumology, University Medical Center Göttingen (UMG), Germany.
Schroeder S; Bayer Pharma AG, Berlin, Germany.
Atar D; Department of Cardiology B, Oslo University Hospital Ulleval and University of Oslo, Norway.
Bax JJ; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Ceconi C; Unit of Cardiology, Hospital of Desenzano del Garda, Desenzano del Garda, Italy.
Cowie MR; National Heart and Lung Institute, Imperial College London, London, UK.
Crisp A; GlaxoSmithKline, Middlesex, UK.
Dominjon F; Servier International, Paris, France.
Ford I; Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Ghofrani HA; University of Giessen and Marburg Lung Center, UGMLC [member of the German Center for Lung Research (DZL)], Giessen, Germany.; Kerckhoff-Klinik Bad Nauheim, Germany.; Imperial College London, UK.
Gropper S; Boehringer-Ingelheim GmBH & Co. KG, Ingelheim, Germany.
Hindricks G; Department of Electrophysiology, Heart Center, University of Leipzig, Leipzig, Germany.
Hlatky MA; Stanford University School of Medicine, Stanford, CA, USA.
Holcomb R; Independent Biostatistician, Minneapolis, MN, USA.
Honarpour N; Amgen, Inc., Thousand Oaks, CA, USA.
Jukema JW; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Kim AM; Pfizer, Inc., Cambridge, MA, USA.
Kunz M; Bayer Pharma AG, Berlin, Germany.
Lefkowitz M; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Le Floch C; Servier International, Paris, France.
Landmesser U; Department of Cardiology, Charité Universitätsmedizin Berlin, Berlin, Germany.
McDonagh TA; King's College Hospital, London, UK.
McMurray JJ; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Merkely B; Semmelweis University Heart and Vascular Center, Budapest, Hungary.
Packer M; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Prasad K; United Kingdom Medicines and Healthcare Products Regulatory Agency, London, UK.
Revkin J; Pfizer, Inc., Cambridge, MA, USA.
Rosano GM; IRCCS San Raffaele Hospital Roma, Rome, Italy.; Cardiovascular and Cell Sciences Institute, St. George's University of London, London, UK.
Somaratne R; Amgen, Inc., Thousand Oaks, CA, USA.
Stough WG; Campbell University College of Pharmacy and Health Sciences, NC, USA.
Voors AA; University of Groningen, Groningen, The Netherlands.
Ruschitzka F; Department of Cardiology, Heart Failure Clinic and Transplantation, University Heart Center Zurich, Zurich, Switzerland.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 May; Vol. 18 (5), pp. 482-9. Date of Electronic Publication: 2016 Apr 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hospitalization*
Mortality*
Heart Failure/*therapy
Activities of Daily Living ; Cause of Death ; Clinical Trials as Topic ; Humans ; Outcome Assessment, Health Care ; Quality of Life ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Trials and the 'real world' - how different are they?
Autorzy:
McMurray JJ; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, Scotland, UK.
Køber L; Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Apr; Vol. 18 (4), pp. 411-3. Date of Electronic Publication: 2016 Mar 28.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Heart Failure*
Humans
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF.
Autorzy:
Samsky MD; Duke University, Durham, NC, USA.
Dunning A; Duke Clinical Research Institute, Durham, NC, USA.
DeVore AD; Duke University, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Schulte PJ; Duke Clinical Research Institute, Durham, NC, USA.
Starling RC; Cleveland Clinic Foundation, Cleveland, OH, USA.
Tang WH; Cleveland Clinic Foundation, Cleveland, OH, USA.
Armstrong PW; Canadian VIGOUR Centre.; University of Alberta, Edmonton, Alberta, Canada.
Ezekowitz JA; University of Alberta, Edmonton, Alberta, Canada.
Butler J; Stony Brook University Hospital, Stony Brook, NY, USA.
McMurray JJ; Glasgow Cardiovascular Research Centre.; University of Glasgow,, Glasgow, UK.
Teerlink JR; San Francisco VA Hospital, University of California, San Francisco and San Francisco VAMC, San Francisco, CA, USA.
Voors AA; University of Groningen, Groningen, the Netherlands.
Metra M; University of Brescia, Brescia, Italy.
Mentz RJ; Duke University, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
O'Connor CM; Duke University, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Patel CB; Duke University, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Hernandez AF; Duke University, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Apr; Vol. 18 (4), pp. 424-32. Date of Electronic Publication: 2015 Dec 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Mortality*
Alanine Transaminase/*blood
Aspartate Aminotransferases/*blood
Bilirubin/*blood
Heart Failure/*blood
Acute Disease ; Aged ; Cause of Death ; Female ; Heart Failure/physiopathology ; Humans ; Liver Function Tests ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Patient Readmission ; Prognosis ; Proportional Hazards Models ; Stroke Volume
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy.
Autorzy:
Perez AL; Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
Grodin JL; Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
Wu Y; Cleveland State University, Department of Mathematics, Cleveland, OH, USA.
Hernandez AF; Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
Butler J; Cardiovascular Division, Stony Brook University, Stony Brook, NY, USA.
Metra M; Institute of Cardiology, University of Brescia, Brescia, Italy.
Felker GM; Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
Voors AA; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
McMurray JJ; Department of Cardiology, University of Glasgow, Glasgow, UK.
Armstrong PW; Department of Cardiology, University of Alberta, Edmonton, Canada.
Starling RC; Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
O'Connor CM; Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
Tang WH; Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Mar; Vol. 18 (3), pp. 290-7. Date of Electronic Publication: 2015 Dec 14.
Typ publikacji:
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Endothelin-1/*blood
Heart Failure/*blood
Heart Failure/*mortality
Acute Disease ; Aged ; Biomarkers/blood ; Female ; Hospital Mortality ; Humans ; Male ; Middle Aged ; Natriuretic Peptide, Brain/blood ; Peptide Fragments/blood ; Prognosis ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
Autorzy:
Damman K; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; University of Groningen, Department of Cardiology, University Medical Centre Groningen, Hanzeplein 1, 9700RB, Groningen, the Netherlands.
Kjekshus J; Centre for Heart Failure Research, Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Wikstrand J; Sahlgrenska University, Hospital, Gothenburg, Sweden.
Cleland JG; National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK.
Komajda M; Department of Cardiology, Pitie Salpetriere Hospital, University Pierre et Marie Curie, Paris, France.
Wedel H; University of Gothenburg, Gothenburg, Sweden.
Waagstein F; Sahlgrenska University, Hospital, Gothenburg, Sweden.
McMurray JJ; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Mar; Vol. 18 (3), pp. 328-36. Date of Electronic Publication: 2015 Dec 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure/*drug therapy
Kidney/*drug effects
Kidney Diseases/*etiology
Sodium Potassium Chloride Symporter Inhibitors/*adverse effects
Aged ; Aged, 80 and over ; Chronic Disease ; Dose-Response Relationship, Drug ; Female ; Furosemide/administration & dosage ; Glomerular Filtration Rate ; Heart Failure/physiopathology ; Humans ; Kidney Diseases/chemically induced ; Kidney Diseases/physiopathology ; Male ; Propensity Score ; Randomized Controlled Trials as Topic ; Retrospective Studies ; Sodium Potassium Chloride Symporter Inhibitors/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF.
Autorzy:
Ambrosy AP; Duke University Medical Center, Durham, NC, USA.
Hernandez AF; Duke University Medical Center, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Armstrong PW; University of Alberta, Edmonton, Alberta, Canada.
Butler J; Stony Brook Heart Institute, Stony Brook, NY, USA.
Dunning A; Duke Clinical Research Institute, Durham, NC, USA.
Ezekowitz JA; University of Alberta, Edmonton, Alberta, Canada.
Felker GM; Duke University Medical Center, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Greene SJ; Duke University Medical Center, Durham, NC, USA.
Kaul P; University of Alberta, Edmonton, Alberta, Canada.
McMurray JJ; University of Glasgow, Glasgow, UK.
Metra M; University of Brescia, Brescia, Italy.
O'Connor CM; Duke University Medical Center, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Reed SD; Duke Clinical Research Institute, Durham, NC, USA.
Schulte PJ; Duke Clinical Research Institute, Durham, NC, USA.
Starling RC; Cleveland Clinic, Cleveland, OH, USA.
Tang WH; Cleveland Clinic, Cleveland, OH, USA.
Voors AA; University of Groningen, Groningen, The Netherlands.
Mentz RJ; Duke University Medical Center, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Mar; Vol. 18 (3), pp. 306-13. Date of Electronic Publication: 2015 Oct 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Health Status*
Quality of Life*
Heart Failure/*diagnosis
Aged ; Aged, 80 and over ; Disease Progression ; Female ; Heart Failure/therapy ; Hospitalization ; Humans ; Male ; Middle Aged ; Randomized Controlled Trials as Topic ; Surveys and Questionnaires
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease.
Autorzy:
Bello NA; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.; Division of Cardiology, Columbia University Medical Center, New York, NY, USA.
Lewis EF; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Desai AS; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Anand IS; VA Medical Center and University of Minnesota, Minneapolis, MN, USA.
Krum H; Monash University and the Alfred Hospital, Victoria, Australia.
McMurray JJ; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Olson K; Amgen, Thousand Oaks, CA, USA.
Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Swedberg K; University of Gothenburg, Gothenburg, Sweden.
van Veldhuisen DJ; University Medical Center Groningen, Groningen, The Netherlands.
Young JB; Cleveland Clinic, Cleveland, OH, USA.
Pfeffer MA; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Nov; Vol. 17 (11), pp. 1201-7. Date of Electronic Publication: 2015 Oct 01.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Anemia*/complications
Anemia*/drug therapy
Darbepoetin alfa*/administration & dosage
Darbepoetin alfa*/adverse effects
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/diagnosis
Renal Insufficiency, Chronic*/complications
Renal Insufficiency, Chronic*/diagnosis
Stroke*/epidemiology
Stroke*/etiology
Stroke*/prevention & control
Heart Failure/*complications
Aged ; Aged, 80 and over ; Female ; Glomerular Filtration Rate ; Hematinics/administration & dosage ; Hematinics/adverse effects ; Humans ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Risk Assessment ; Risk Factors ; Statistics as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis.
Autorzy:
Simpson J; BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.
Castagno D; Division of Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy.
Doughty RN; Department of Medicine and National Institute of Health Innovation, University of Auckland, Auckland, New Zealand.
Poppe KK; Department of Medicine and National Institute of Health Innovation, University of Auckland, Auckland, New Zealand.
Earle N; Department of Medicine and National Institute of Health Innovation, University of Auckland, Auckland, New Zealand.
Squire I; University of Leicester, Department of Cardiovascular Sciences and NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK.
Richards M; University of Otago, Christchurch, Department of Medicine, Christchurch, New Zealand.
Andersson B; Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden.
Ezekowitz JA; Division of Cardiology and Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada.
Komajda M; Université Paris 6, Pitié Salpetrière Hospital, Paris, France.
Petrie MC; Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Agamemnon Street, Clydebank, UK.
McAlister FA; The Division of General Internal Medicine, University of Alberta, Edmonton, Canada.
Gamble GD; Department of Medicine and National Institute of Health Innovation, University of Auckland, Auckland, New Zealand.
Whalley GA; Faculty of Social and Health Sciences, Unitec, Auckland, New Zealand.
McMurray JJ; BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.
Pokaż więcej
Corporate Authors:
Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC)
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Nov; Vol. 17 (11), pp. 1182-91. Date of Electronic Publication: 2015 Sep 11.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms:
Atrial Fibrillation*/complications
Atrial Fibrillation*/diagnosis
Atrial Fibrillation*/drug therapy
Atrial Fibrillation*/physiopathology
Heart Failure*/complications
Heart Failure*/diagnosis
Heart Failure*/mortality
Heart Failure*/physiopathology
Adrenergic beta-Antagonists/*therapeutic use
Heart Rate/*physiology
Aged ; Cause of Death ; Female ; Humans ; Hypertension/physiopathology ; Male ; Prognosis ; Proportional Hazards Models ; Risk Factors ; Statistics as Topic ; Stroke Volume/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics.
Autorzy:
Krum H; Centre of Cardiovascular Research & Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.
McMurray JJ; British Heart Foundation Research Centre, University of Glasgow, 126 University Place, Glasgow, 126 University Place, Scotland, UK.
Abraham WT; Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.
Dickstein K; Stavanger University Hospital, Stavanger, Norway and Institute of Internal Medicine, University of Bergen, Bergen, Norway.
Køber L; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Desai AS; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Solomon SD; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Chiang Y; Novartis Pharma AG, Basel, Switzerland.
Gimpelewicz C; Novartis Pharma AG, Basel, Switzerland.
Reimund B; Novartis Pharma AG, Basel, Switzerland.
Ali MA; Novartis Pharma AG, Basel, Switzerland.
Tarnesby G; Novartis Pharma AG, Basel, Switzerland.
Massie BM; University of California, San Francisco, CA, USA.
Pokaż więcej
Corporate Authors:
ATMOSPHERE Committees and Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Oct; Vol. 17 (10), pp. 1075-83.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Amides/*administration & dosage
Fumarates/*administration & dosage
Heart Failure/*drug therapy
Renin/*antagonists & inhibitors
Angiotensin-Converting Enzyme Inhibitors/administration & dosage ; Cardiovascular Agents/administration & dosage ; Diabetes Mellitus ; Drug Therapy, Combination ; Enalapril/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Stroke Volume ; Ventricular Dysfunction, Left/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
Autorzy:
Kao DP; University of Colorado School of Medicine, Aurora, CO, USA.
Lewsey JD; University of Glasgow, Glasgow, UK.
Anand IS; Veterans Affairs Medical Center and University of Minnesota, Minneapolis, MN, USA.
Massie BM; University of California San Francisco, San Francisco, CA, USA.
Zile MR; Medical University of South Carolina and the RHF Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Carson PE; Washington Veterans Affairs Medical Center and Georgetown University, Washington, DC, USA.
McKelvie RS; Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada.
Komajda M; University Pierre et Marie Curie Paris VI, La Pitié-Salpétrière Hospital Paris, France.
McMurray JJ; University of Glasgow, Glasgow, UK.
Lindenfeld J; University of Colorado School of Medicine, Aurora, CO, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Sep; Vol. 17 (9), pp. 925-35. Date of Electronic Publication: 2015 Aug 06.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Biphenyl Compounds/*administration & dosage
Heart Failure/*physiopathology
Stroke Volume/*physiology
Tetrazoles/*administration & dosage
Aged ; Aged, 80 and over ; Angiotensin II ; Angiotensin II Type 1 Receptor Blockers/administration & dosage ; Cause of Death/trends ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Heart Failure/drug therapy ; Heart Failure/mortality ; Humans ; Irbesartan ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Survival Rate/trends ; United Kingdom/epidemiology ; United States/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review.
Autorzy:
Platz E; Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jhund PS; BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Campbell RT; BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
McMurray JJ; BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Sep; Vol. 17 (9), pp. 906-16. Date of Electronic Publication: 2015 Jul 31.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; Systematic Review
MeSH Terms:
Clinical Trials as Topic*
Disease Management*
Pulmonary Edema*/epidemiology
Pulmonary Edema*/etiology
Pulmonary Edema*/therapy
Heart Failure/*complications
Acute Disease ; Global Health ; Heart Failure/therapy ; Humans ; Morbidity/trends ; Prevalence ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Autorzy:
Askevold ET; Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; K. G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, Oslo, Norway.
Gullestad L; Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; K. G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, Oslo, Norway.
Nymo S; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Kjekshus J; Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; K. G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, Oslo, Norway.
Yndestad A; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; K. G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, Oslo, Norway; K. G. Jebsen Inflammatory Research Center, Oslo, Norway.
Latini R; IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milano, Italy.
Cleland JG; Department of Cardiology, Hull York Medical School, University of Hull, Castle Hill Hospital, Kingston-upon-Hull, United Kingdom.
McMurray JJ; British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Aukrust P; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; K. G. Jebsen Inflammatory Research Center, Oslo, Norway; K. G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway.
Ueland T; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; K. G. Jebsen Inflammatory Research Center, Oslo, Norway; K. G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Aug 19; Vol. 10 (8), pp. e0133970. Date of Electronic Publication: 2015 Aug 19 (Print Publication: 2015).
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure/*blood
Heart Failure/*drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Proteins/*analysis
Rosuvastatin Calcium/*therapeutic use
Aged ; Chronic Disease ; Female ; Heart Failure/diagnosis ; Humans ; Male ; Middle Aged ; Prognosis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Autorzy:
Jhund PS; BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Anand IS; Veterans Affairs Medical Center and University of Minnesota, Minneapolis, MN, USA.
Komajda M; Université Paris 6 and Hospital Pitié-Salpêtrière, Paris, France.
Claggett BL; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
McKelvie RS; Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
Zile MR; Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, SC, USA.
Carson PE; Georgetown University and Washington DC Veterans Affairs Medical Center, Washington, DC, USA.
McMurray JJ; BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Aug; Vol. 17 (8), pp. 809-17. Date of Electronic Publication: 2015 Apr 29.
Typ publikacji:
Journal Article
MeSH Terms:
Biomarkers/*blood
Heart Failure/*physiopathology
Natriuretic Peptide, Brain/*blood
Peptide Fragments/*blood
Aged ; Female ; Heart Failure/blood ; Heart Failure/mortality ; Hospitalization ; Humans ; Male ; Prognosis ; Stroke Volume ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
Autorzy:
Cannon JA; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Collier TJ; London School of Hygiene & Tropical Medicine, London, UK.
Shen L; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Swedberg K; University of Gothenburg, Gothenburg, Sweden.
Krum H; Monash University, Melbourne, Australia.
Van Veldhuisen DJ; University Medical Centre Groningen, The Netherlands.
Vincent J; Pfizer Pharma, NY, USA.
Pocock SJ; London School of Hygiene & Tropical Medicine, London, UK.
Pitt B; University of Michigan, MI, USA.
Zannad F; Nancy Université, Nancy, France Inserm, Université de Lorraine and CHU de Nancy, Nancy, France.
McMurray JJ; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Jul; Vol. 17 (7), pp. 707-16.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Electrocardiography*
Heart Failure/*drug therapy
Hospitalization/*statistics & numerical data
Mineralocorticoid Receptor Antagonists/*therapeutic use
Spironolactone/*analogs & derivatives
Aged ; Double-Blind Method ; Eplerenone ; Female ; Heart Failure/mortality ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Random Allocation ; Spironolactone/therapeutic use ; Stroke Volume/physiology ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Autorzy:
Voors AA; Department of Cardiology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Gori M
Liu LC
Claggett B
Zile MR
Pieske B
McMurray JJ
Packer M
Shi V
Lefkowitz MP
Solomon SD
Pokaż więcej
Corporate Authors:
PARAMOUNT Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 May; Vol. 17 (5), pp. 510-7. Date of Electronic Publication: 2015 Feb 06.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Stroke Volume*
Aminobutyrates/*therapeutic use
Angiotensin Receptor Antagonists/*therapeutic use
Heart Failure/*drug therapy
Kidney/*physiopathology
Neprilysin/*antagonists & inhibitors
Tetrazoles/*therapeutic use
Aged ; Aged, 80 and over ; Angiotensin II Type 1 Receptor Blockers/therapeutic use ; Biphenyl Compounds ; Creatinine/blood ; Double-Blind Method ; Drug Combinations ; Female ; Glomerular Filtration Rate ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Valsartan/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 61-80 z 192

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies